Spangemacher M

Department of Molecular Neuroimaging, Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.

6 papers · 2 preprints · ORCID

ArticlePsilocybin

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression: 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Mertens LJ, Betzler F, Brand M +24

Europe PMC2026
PreprintPsilocybin

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”

Wolff M, Kangaslampi S, Zeifman R +1

Europe PMC2026
ArticlePsilocybin

Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression: The EPISODE Randomized Clinical Trial.

Mertens LJ, Koslowski M, Betzler F +23

Europe PMC2026
PreprintPsilocybin

Strong alliance, weak conclusions: Comment on Goodwin et al. (2026) “The role of therapeutic alliance in psilocybin treatment for treatment-resistant depression”

Wolff M, Kangaslampi S, Zeifman R +1

Europe PMC2026
ArticlePsychedelics

Psychedelics: The pathway to implementation in the European healthcare systems.

Gründer G, Mertens LJ, Spangemacher M +2

Europe PMC2026
ArticlePsilocybin

Compassionate use of psilocybin for treatment-resistant depression in Germany.

Gründer G, Mertens LJ, Jungaberle A +2

Europe PMC2026
ArticleKetamine

[Mechanisms of action of antidepressive pharmacotherapy: brain and mind-body and environment].

Spangemacher M, Reinwald J, Adolphi H +4

Europe PMC2025
ArticlePsilocybin

Psilocybin as a Disease-Modifying Drug—A Salutogenic Approach in Psychiatry.

Spangemacher M, Mertens LJ, Färber LV +3

Europe PMC2024